Drug intelligence / Profile preview

ursodeoxycholic acid + total glucosides of paeony

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of ursodeoxycholic acid (UDCA) and total glucosides of paeony (TGP). UDCA is a naturally occurring bile acid that constitutes a minor fraction of the human bile acid pool and is used to treat liver diseases by replacing more toxic bile acids. TGP is an active compound extracted from the dried roots of Paeonia lactiflora Pall with immunomodulatory and anti-inflammatory properties. This combination is being investigated for the treatment of primary biliary cholangitis (PBC) with autoimmune hepatitis (AIH) features.

Targets

ABCB11 (Bile salt export pump)FXR (Farnesoid x-activated receptor)

Beyond the preview

Go deeper on ursodeoxycholic acid + total glucosides of paeony.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ursodeoxycholic acid + total glucosides of paeony.

Explore the full profile